Adeno-associated virus (AAV) vectors are highly regarded for their ability to deliver therapeutic genes effectively, with several approved therapies validating their clinical utility. Despite this, pre-existing immunity to AAV capsids can significantly reduce therapeutic outcomes and increase the risk of adverse events. Extracellular vesicle (EV)-encapsulation of AAV provides a dual advantage: it shields the capsid from neutralizing antibodies and improves gene delivery efficiency through vesicle-mediated cellular uptake. Researchers from Massachusetts General Hospital and Harvard Medical School recently published a study that elucidates critical aspects of EV-AAV biology, highlights optimization strategies for its production, and demonstrates its functional advantages over conventional AAV vectors.

Characterization and Quantification of EV-AAV

Recent efforts to characterize EV-AAV have employed advanced methods such as iodixanol density gradient ultracentrifugation, which separates EV-AAV from free AAV particles with high precision. Notable findings include:

  • EV-AAV constitutes 0.5% to 12% of total AAV production across various serotypes, with AAV6 exhibiting the highest proportion of EV-AAV (11.95%) and AAV8 the lowest (0.5%).
  • Cryo-electron microscopy has revealed that AAV capsids are present both on the surface and within the lumen of EVs, offering unique structural insights.

Functional Superiority of Intraluminal EV-AAV

A critical advantage of EV-AAV is the presence of intraluminal AAV capsids, which:

  1. Demonstrate resistance to neutralizing antibodies.
  2. Retain the ability to transduce cells effectively.

In vivo experiments have shown that intraluminal EV-AAV9 mediates efficient transduction of neurons when injected into the striatum of mice. While the overall transduction efficiency of intraluminal EV-AAV is lower than total EV-AAV preparations, its immune-evasive properties make it particularly valuable in immune-challenged environments.

Optimizing EV-AAV Production

One limitation of EV-AAV is its relatively low production yield compared to conventional AAV. The membrane-associated accessory protein (MAAP) has emerged as a critical factor in addressing this challenge:

  •  Trans expression of MAAP8 during AAV9 production increased EV-AAV yields by 5.6-fold.
  • MAAP facilitates the release of AAV particles into the extracellular milieu, enhancing both EV-associated and free AAV production.

These findings underscore the potential of MAAP engineering to improve the scalability of EV-AAV production for clinical applications.

The Essential Role of the AAV Capsid

Functional studies confirm that the AAV capsid remains indispensable for EV-AAV transduction. Experiments comparing EV-AAV preparations with and without capsids revealed:

  • A 9-fold higher transduction efficiency for capsid-containing EV-AAV, highlighting the capsid’s role in nuclear delivery and intracellular trafficking.
  • Capsid-less EV preparations show minimal transgene expression, likely due to limited nuclear entry.

Therapeutic Implications and Future Directions

The insights gained from recent studies provide a roadmap for advancing EV-AAV technology. Key areas for further research include:

  1. Improving Production Yields: Combining MAAP overexpression with strategies to selectively package AAV into EVs can enhance yields and reduce free AAV contamination.
  2. Exploring Serotype-Specific Differences: Understanding why serotypes like AAV6 produce higher proportions of EV-AAV could guide the engineering of more efficient vectors.
  3. Optimizing Intraluminal Packaging: Developing methods to increase the proportion of intraluminal AAV capsids may enhance immune evasion.
  4. Scaling Up Manufacturing: Adapting EV-AAV production to bioreactor systems and chromatographic purification can facilitate clinical translation.
  5. Targeting Specific Tissues: Investigating the biodistribution and tropism of EV-AAV will enable the design of tissue-specific delivery systems, particularly for CNS and systemic disorders.

Conclusion

EV-AAV vectors represent a transformative innovation in gene therapy, combining the immune evasion of EVs with the precision and efficacy of AAV. By addressing challenges such as immune neutralization, production scalability, and tissue targeting, EV-AAV has the potential to overcome many limitations of conventional AAV systems. Ongoing research into its biology and optimization will pave the way for broader clinical applications, expanding the reach of gene therapy to previously untreatable conditions.

Reference

Probing aspects of extracellular vesicle (EV)-associated AAV biology and composition allows increased vector yield and insight into its transduction and immune-evasive properties. 

MarinBio Publications and Presentations on Gene Therapy

American Society of Hematology (ASH) Annual Meeting 2024

Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Gene Therapy Assay Services Offered by MarinBio

Contact us at 415.883.8000 or email us at info@marinbio.com with any questions about in vitro or cell based assays for gene therapy development.

Molecular Biology & qPCR 

  • Viral vector & plasmid construction (research grade & small-scale GMP grade)
  • Infectious genome and vector genome titers
  • Residual host DNA quantitation

ELISA & Immunoassays

  • Protein titer by ELISA
  • Residual host protein quantitation
  • Pharmacokinetics (PK) assays
  • Pharmacodynamics (PD) assays

Cell-Based Assays for gene therapy drugs

  • Gene-specific functional assays
  • Reporter assays
  • Development of customized reporter assays

Flow cytometry assays for gene therapy products

  • Infectious titer by flow cytometry
  • Gene delivery and potency assays

Immunogenicity assays 

  • ADCC, Antibody-Dependent Cellular Cytotoxicity bioassays
  • ADA, Anti-Drug Antibody inhibiting drug action
  • T-cell assays: Peripheral blood mononuclear cell (PBMC)- and dendritic cell (DC)- based assays.
  • Cytokine Release Syndrome Assay
  • Natural Killer (NK) Cell Assay
  • Phagocytosis Assay

Potency assays 

In vitro and cell-based assays are used to measure the biological activity of a therapeutic product and confirm its ability to achieve its intended effect.

Stability testing

In vitro and cell-based assays to test the bioactivity of manufactured drug lots over time under various conditions.

Lot Release Testing

In vitro and cell-based assays are used to test each batch of a gene therapy product to ensure it meets safety, potency, purity, and quality standards before distribution.

Production and characterization of a GMP Master Cell Bank for vector production and cell-based assays